Pimozide

Amber-G

Brand Name(s):Orap

Indication:Antipsychotic – patients on the SMI register

Rationale:

Considered:Jun-09

Review Date:Oct-24

Comments:
NICE CG178
Psychosis and schizophrenia in adults: treatment and management
Full details at:https://www.nice.org.uk/guidance/cg178/resources/guidance-psychosis-and-schizophrenia-in-adults-treatment-and-management-pdf
Feb 2014

…………………………
National Clinical Guideline Number CG155
January 2013
Guidance available at: http://www.nice.org.uk/nicemedia/live/14021/62392/62392.pdf
…………………………Antipsychotic use may be associated with an increased risk of VTE. At present there are insufficient data available to determine any difference in risk between atypical and conventional antipsychotics, or between individual drugs. All possible risk factors for VTE should be identified before and during antipsychotic treatment and preventive measures undertaken

MHRA Drug safety update Volume 2 Issue 11 June 2009